Domingo Gargallo-Viola

Domingo Gargallo-Viola has extensive experience in the pharmaceutical industry, particularly in the field of infectious diseases. Domingo is the Co-founder, CEO, and CSO of ABAC Therapeutics, a start-up focused on precision antibacterial agents. Domingo led the spin-out of this project from Ferrer and is responsible for promoting the application of precision medicine to infectious disease treatment. Domingo is also the intellectual owner of the PasNas algorithm, which is a novel drug discovery strategy aimed at improving the efficiency of the drug development process.

Before their role at ABAC Therapeutics, Domingo worked at Grupo Ferrer Internacional from 2008 to 2015. Domingo served as the Infectious Diseases Manager and Head of Pharmacology, Toxicology, and Safety Pharmacology. Domingo managed the portfolio and spearheaded a transformative pipeline that expanded the company's profile in the infectious diseases field. In this role, Domingo played a key role in bringing ozenoxacin, a new non-fluorinated quinolone, to the market.

Prior to their time at Grupo Ferrer Internacional, Domingo worked at GlaxoSmithKline from 2000 to 2008. Domingo held multiple roles including Drug Discovery Biology Director, Portfolio Manager, and Project Leader. Domingo was responsible for coordinating scientific units involved in discovery, building and managing high-performing teams, and establishing portfolio priorities. Domingo's work at GlaxoSmithKline led to the discovery of several first-in-class drug candidates.

Domingo's career in the pharmaceutical industry began at Glaxo Wellcome (later GSK) in 1990, where they served as the Head of Mycology and Chemotherapy Departments. Domingo was responsible for designing and constructing laboratories, selecting and managing human teams, and defining strategies in the Biology Area. Domingo also worked at Glaxo (later Glaxo Wellcome and GSK) as the Head of Microbiology and Chemotherapy Departments from 1993 to 1999.

Before entering the pharmaceutical industry, Domingo worked as a Research Associate at the United States Department of Defense, Uniformed Services University of the Health Sciences. Domingo also served as an Assistant Professor at the University of Barcelona, Department of Microbiology and Parasitology.

Overall, Domingo Gargallo-Viola has a wealth of experience in the pharmaceutical industry, particularly in the areas of infectious diseases, drug discovery, and portfolio management. Domingo has played key roles in bringing innovative drugs to market and has a strong focus on improving the efficiency and success rate of the drug development process.

Domingo Gargallo-Viola has a diverse education history. Domingo attended the Universitat de Barcelona from 1982 to 1987, where they obtained a PhD in Biological Sciences with distinction (cum laude). In 1994, they pursued additional education at CIEMAT - National Nuclear Safety Council, specializing in the supervision of radioactive facilities in the fields of biomedicine and research. Following this, they attended IE Business School from 1997 to 1998 and later the IESE Business School from 1998 to 1999, completing a Management Development Program (MDP) at both institutions.